Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of crushed Stribild versus whole tablet with breakfast or drip feed
NL-OMON40850Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Radboud University Medical Center. Primary endpoints: Primary bioequivalence endpoint: intervention I versus reference and Primary bioequivalence endpoint: intervention II versus reference. Started Jan 2015; status: active, not recruiting.
02
Drugs
emtricitabine + elvitegravir + cobicistat + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON40850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40850.